S
CNTX icon

swisspartners’s Context Therapeutics CNTX Stock Holding History

swisspartners’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$119K Buy
180,000
+95,000
+112% +$102K 0.15% 70
2022
Q3 		$94K Buy
85,000
+42,765
+101% +$77K 0.1% 76
2022
Q2 		$92K Hold
42,235
– – 0.09% 75
2022
Q1 		$92K Hold
42,235
– – 0.07% 81
2021
Q4 		$114K Buy
+42,235
New +$211K 0.08% 82

Other funds holding CNTX

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MCCA
Mill Creek Capital Advisors Conshohocken, Pennsylvania $4.87B AUM 17.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

swisspartners's CNTX Position: Q4 2022 in Review

swisspartners increased its Context Therapeutics (CNTX) stake by 112% in Q4 2022, buying an estimated $102K and bringing the position to 180,000 shares worth $119K. The position accounts for 0.15% of the portfolio, ranked #70.

swisspartners first reported a position in CNTX in Q4 2021 and has held it in 5 quarters since. 24 funds tracked by Wall St. Rank hold CNTX as of Q4 2022.

  • swisspartners held 180,000 shares of Context Therapeutics worth $119K as of Q4 2022.
  • swisspartners bought 95,000 Context Therapeutics shares in Q4 2022, an estimated $102K.
  • Context Therapeutics made up 0.15% of swisspartners's portfolio in Q4 2022, its #70 holding.
  • swisspartners first reported a position in Context Therapeutics in Q4 2021 and has held it in 5 quarters since.
  • 24 funds tracked by Wall St. Rank held Context Therapeutics as of Q4 2022.

Based on swisspartners's 13F filing for Q4 2022, filed 14 Feb 2023.